KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Short-term Investments: 2015-2023

Historic Short-term Investments for BeOne Medicines (ONC) over the last 9 years, with Dec 2023 value amounting to $2.6 million.

  • BeOne Medicines' Short-term Investments fell 99.61% to $2.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.6 million, marking a year-over-year decrease of 99.61%. This contributed to the annual value of $2.6 million for FY2023, which is 99.61% down from last year.
  • Per BeOne Medicines' latest filing, its Short-term Investments stood at $2.6 million for FY2023, which was down 99.61% from $665.3 million recorded in FY2022.
  • In the past 5 years, BeOne Medicines' Short-term Investments registered a high of $3.3 billion during FY2020, and its lowest value of $2.6 million during FY2023.
  • In the last 3 years, BeOne Medicines' Short-term Investments had a median value of $665.3 million in 2022 and averaged $969.9 million.
  • Per our database at Business Quant, BeOne Medicines' Short-term Investments spiked by 796.21% in 2020 and then crashed by 99.61% in 2023.
  • BeOne Medicines' Short-term Investments (Yearly) stood at $364.7 million in 2019, then skyrocketed by 796.21% to $3.3 billion in 2020, then slumped by 31.41% to $2.2 billion in 2021, then slumped by 70.33% to $665.3 million in 2022, then tumbled by 99.61% to $2.6 million in 2023.